1. [The relationship between inflammatory markers and the risk of lung cancer: a prospective cohort study].
- Author
-
Wang G, Wei LP, Li N, Xu WG, Su K, Li F, Tan FW, Lyu ZY, Feng XS, Li X, Chen HD, Chen YH, Guo LW, Cui H, Jiao PF, Liu HX, Ren JS, Wu SL, Shi JF, Dai M, and He J
- Subjects
- C-Reactive Protein metabolism, Female, Humans, Leukocyte Count, Lung Neoplasms blood, Male, Neutrophils, Proportional Hazards Models, Prospective Studies, Risk Factors, Lung Neoplasms epidemiology
- Abstract
Objective: To investigate whether elevated levels of C-reactive protein (CRP) and neutrophil (NE) in the blood is associated with an increased risk of lung cancer incidence. Methods: From 2006 to 2007, all employees and retirees from Kailuan (Group) Limited liability Corporation were included in this Kailuan Cohort study. The last follow-up date was December 2015. Data on new cases of lung cancer were collected, and multivariable Cox proportional hazards regression models were used to the relationship between baseline CRP and NE at baseline and risk of lung cancer. Results: A total of 92 735 participants were enrolled in this study. During the follow-up, 850 new cases of lung cancer were identified. All subjects were divided into four groups according to the combination level of CRP and NE at baseline: CRP≤3 mg/L and NE≤4×10(9)/L(Group A), CRP≤3 mg/L and NE>4×10(9)/L(Group B), CRP>3 mg/L and NE≤4×10(9)/L(Group C), CRP>3 mg/L and NE>4×10(9)/L(Group D). The cumulative incidence of lung cancer were 950/100 000, 1 030/100 000, 1 081/100 000 and 1 596/100 000 in these four groups, respectively ( P <0.001). Multivariate Cox proportional risk model showed that participants from Group D had an significantly increased 72% risks of lung cancer when compared to Group A (95% CI: 1.40~2.12, P <0.001). Stratified analyses gender showed that males in Group D had higher risk of lung cancer when compared with participants in Group A ( HR =1.73, 95% CI: 1.40~2.15, P <0.001). Conclusion: Elevated levels of CRP and NE might increase the risk of lung cancer.
- Published
- 2019
- Full Text
- View/download PDF